Regulating fibrosis and growth through latent TGFbeta binding proteins

Project: Research project

Project Details


Latent TGFβ binding protein 4 (LTBP4) modifies muscular dystrophy in mice and in humans with Duchenne Muscular Dystrophy. LTBP4 is an extracellular matrix protein that binds latent TGFβ to form the large latent complex. With stimulation like injury, LTBPs undergoes a conformational shift and proteolytic cleavage which releases latent TGFβ, which is the first step in its activation. Activated TGFβ has been implicated in fibrosis in many solid organs, and is a prominent feature of dystrophic muscle and injured muscle. Excessive TGFβ is also known to inhibit muscle regeneration. In Duchenne Muscular Dystrophy, the protective LTBP4 variants that predict prolonged ambulation cause reduced TGFβ signaling. Similarly, in mice the protective Ltbp4 allele is linked to reduced TGFβ signaling. LTBP4 binds all three primary TGFβ forms. Overexpression of the protective LTBP4 form in mouse muscle reduces fibrosis and also leads to increased muscle mass in the context of muscular dystrophy. LTBP4 not only binds TGFβ but LTBP4 also binds myostatin. Domain mapping of LTBP4 binding sites demonstrated that TGFβ and myostatin binding is mediated by distinct regions of LTBP4. LTBP4 therefore regulates multiple cytokines by sequestering these molecules in the matrix, rendering them inactive. A mechanism to reduce TGFβ AND myostatin is an attractive target for treating muscular dystrophy since such an approach would reduce muscle fibrosis and promote muscle growth. This proposal outlines experiments designed to better define the mechanism by which LTBP4 acts. The first aim is designed to evaluate the relative contribution of TGFβ and myostatin binding to LTBP4’s effect. The second aim will investigate how manipulating LTBP4 affects fibrosis and muscle recovery after injury and in muscular dystrophy. The third aim will assess the importance of LTBP4’s hinge region since this region mediates its effect as a modifier in muscular dystrophy.
Effective start/end date4/1/181/31/22


  • National Heart, Lung, and Blood Institute (5R01HL140938-04)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.